Form D · Biotechnology
IASO PHARMA INC
San Diego, CA · CIK 0001422702
Offering snapshot reported May 6, 2011 · SEC filing
- Reported sold
- $3M Offering amount: $3M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $100 Reported outside-investor minimum
- First sale
- Apr 29, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 6, 2011 | Initial | $3,000,000 | No comparison | 21 | SEC filing |
| Mar 16, 2010 | Amendment | $3,343,000 | $763,000vs Feb 22, 2010 | 45 | SEC filing |
| Feb 22, 2010 | Initial | $2,580,000 | No comparison | 29 | SEC filing |
| Dec 26, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-159365
Source: Form D, filed May 6, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jai Jun (Matthew) Choung | Director |
| Michael L. Corrado | Director |
| Gary G. Gemignani | Director |
| James W. Klingler | Executive |
| Jonah J. Lobell | Director |
| Jay J Lobell | Director |
| Mark W Lotz | Executive |
| Michael Rice | Director |
| James Rock | Executive |
| Matthew A Wikler | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
12707 High Bluff Drive Suite 200
San Diego, CA, 92130
San Diego, CA, 92130